December 6, 2016 / 1:47 PM / in a year

BRIEF-Helix Biopharma presents topline l-dos47 results

Dec 6 (Reuters) - Helix Biopharma Corp -

* Helix Biopharma Corp presents topline l-dos47 results at the 17th iasclc world conference on lung cancer

* Forty-Four , or 80% of patients in safety population had at least one treatment emergent adverse events Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below